<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459976</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Insights into Genetic and Antigenic Characteristics of Influenza A(H1N1)pdm09 Viruses Circulating in Sicily During the Surveillance Season 2023-2024: The Potential Effect on the Seasonal Vaccine Effectiveness.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1644</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101644</ELocationID><Abstract><AbstractText>After disruption in the influenza circulation due to the emergence of SARS-CoV-2, the intensity of seasonal outbreaks has returned to the pre-pandemic levels. This study aimed to evaluate the evolution and variability of whole-genome sequences of A(H1N1)pdm09, the predominant influenza virus in Sicily (Italy) during the season 2023-2024. The potential vaccine efficacy was calculated using the <i>p</i><sub>epitope</sub> model based on amino acid changes in the dominant epitope of hemagglutinin. The HA gene sequences showed several amino acid substitutions, some of which were within the major antigenic sites. The phylogenetic analysis showed that Sicilian strains grouped into two main genetic clades (6B.1A.5a.2a.1 and 6B.1A.5a.2a) and several subclades. Notably, about 40% of sequences partially drifted from the WHO-recommended vaccine strain A/Victoria/4897/2022 for the Northern Hemisphere. These sequences mostly belonged to the subclades C.1.8 and C.1.9 and harboured the amino acid mutations responsible for the modest predicted vaccine efficacy (E = 38.12% of 53%, <i>p</i><sub>epitope</sub> = 0) against these viruses. Amino acid substitutions in other gene segments were also found. Since influenza viruses are constantly evolving, genomic surveillance is crucial in monitoring their molecular evolution and the occurrence of genetic and antigenic changes, and, thus, their potential impact on vaccine efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tramuto</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0108-4608</Identifier><AffiliationInfo><Affiliation>Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro"-Hygiene Section, University of Palermo, 90127 Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maida</LastName><ForeName>Carmelo Massimo</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6989-9259</Identifier><AffiliationInfo><Affiliation>Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro"-Hygiene Section, University of Palermo, 90127 Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randazzo</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1139-0879</Identifier><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Previti</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sferlazza</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graziano</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5851-5256</Identifier><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantino</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3397-7331</Identifier><AffiliationInfo><Affiliation>Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro"-Hygiene Section, University of Palermo, 90127 Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzucco</LastName><ForeName>Walter</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-5090-1366</Identifier><AffiliationInfo><Affiliation>Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro"-Hygiene Section, University of Palermo, 90127 Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitale</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro"-Hygiene Section, University of Palermo, 90127 Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012802" MajorTopicYN="N" Type="Geographic">Sicily</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="Y">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="Y">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Italy</Keyword><Keyword MajorTopicYN="N">Sicily</Keyword><Keyword MajorTopicYN="N">antigenic drift</Keyword><Keyword MajorTopicYN="N">community</Keyword><Keyword MajorTopicYN="N">influenza virus</Keyword><Keyword MajorTopicYN="N">molecular surveillance</Keyword><Keyword MajorTopicYN="N">vaccine efficacy</Keyword><Keyword MajorTopicYN="N">whole-genome sequencing</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459976</ArticleId><ArticleId IdType="pmc">PMC11512306</ArticleId><ArticleId IdType="doi">10.3390/v16101644</ArticleId><ArticleId IdType="pii">v16101644</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO)  Estimating Disease Burden of Influenza.  [(accessed on 13 September 2024)]; Available online:  https://www.who.int/europe/activities/estimating-disease-burden-of-influenza.</Citation></Reference><Reference><Citation>Derqui N., Nealon J., Mira-Iglesias A., Díez-Domingo J., Mahé C., Chaves S.S. Predictors of influenza severity among hospitalized adults with laboratory confirmed influenza: Analysis of nine influenza seasons from the Valencia region, Spain. Influenza Other Respir. Viruses. 2022;16:862–872. doi: 10.1111/irv.12985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12985</ArticleId><ArticleId IdType="pmc">PMC9343335</ArticleId><ArticleId IdType="pubmed">35411561</ArticleId></ArticleIdList></Reference><Reference><Citation>El Guerche-Séblain C., Etcheto A., Parmentier F., Afshar M., Macias A.E., Puentes E., Gresset-Bourgeois V., Akcay M., Petitjean A., Coudeville L. Hospital admissions with influenza and impact of age and comorbidities on severe clinical outcomes in Brazil and Mexico. PLoS ONE. 2022;17:e0273837. doi: 10.1371/journal.pone.0273837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0273837</ArticleId><ArticleId IdType="pmc">PMC9648751</ArticleId><ArticleId IdType="pubmed">36355793</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinjoh M., Furuichi M., Narabayashi A., Kamei A., Yoshida N., Takahashi T. Risk factors in pediatric hospitalization for influenza A and B during the seven seasons immediately before the COVID-19 era in Japan. J. Infect. Chemother. 2021;27:1735–1742. doi: 10.1016/j.jiac.2021.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2021.08.020</ArticleId><ArticleId IdType="pubmed">34454832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramuto F., Restivo V., Costantino C., Colomba G.M.E., Maida C.M., Casuccio A., Vitale F. Surveillance Data for Eight Consecutive Influenza Seasons in Sicily, Italy. Am. J. Trop. Med. Hyg. 2019;101:1232–1239. doi: 10.4269/ajtmh.19-0059.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.19-0059</ArticleId><ArticleId IdType="pmc">PMC6896868</ArticleId><ArticleId IdType="pubmed">31571567</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharpure R., Olsen S.J., Davis W.W. Quantified impacts of non-pharmaceutical interventions on influenza circulation during the COVID-19 pandemic in 13 African countries, 2020–2022. Influenza Other Respir. Viruses. 2024;18:e13241. doi: 10.1111/irv.13241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13241</ArticleId><ArticleId IdType="pmc">PMC10796249</ArticleId><ArticleId IdType="pubmed">38249442</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Neill G.K., Taylor J., Kok J., Dwyer D.E., Dilcher M., Hua H., Levy A., Smith D., Minney-Smith C.A., Wood T., et al. Circulation of influenza and other respiratory viruses during the COVID-19 pandemic in Australia and New Zealand, 2020–2021. West. Pac. Surveill. Response J. 2023;14:1–9. doi: 10.5365/wpsar.2023.14.3.948.</Citation><ArticleIdList><ArticleId IdType="doi">10.5365/wpsar.2023.14.3.948</ArticleId><ArticleId IdType="pmc">PMC10630701</ArticleId><ArticleId IdType="pubmed">37946717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramuto F., Mazzucco W., Maida C.M., Colomba G.M.E., Di Naro D., Coffaro F., Graziano G., Costantino C., Restivo V., Vitale F. COVID-19 emergency in Sicily and intersection with the 2019–2020 influenza epidemic. J. Prev. Med. Hyg. 2021;62:E10–E12. doi: 10.15167/2421-4248/jpmh2021.62.1.1870.</Citation><ArticleIdList><ArticleId IdType="doi">10.15167/2421-4248/jpmh2021.62.1.1870</ArticleId><ArticleId IdType="pmc">PMC8283625</ArticleId><ArticleId IdType="pubmed">34322611</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung C., Konya L., Su L. Postpandemic immunity debt of influenza in the USA and England: An interrupted time series study. Public Health. 2024;227:239–242. doi: 10.1016/j.puhe.2023.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2023.12.009</ArticleId><ArticleId IdType="pubmed">38246119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F., Chen M.T., Zhang L., Wu M., Xie H., Guan Z.X., Yang Z., Cai Z.X., Wen J.Z., Yang L.Y. Resurgence of influenza A after SARS-CoV-2 omicron wave and comparative analysis of hospitalized children with COVID-19 and influenza A virus infection. Front. Med. 2024;10:1289487. doi: 10.3389/fmed.2023.1289487.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1289487</ArticleId><ArticleId IdType="pmc">PMC10810023</ArticleId><ArticleId IdType="pubmed">38274442</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W., Gu L. Resurgence of seasonal influenza driven by A/H3N2 and B/Victoria in succession during the 2023–2024 season in Beijing showing increased population susceptibility. J. Med. Virol. 2024;96:e29751. doi: 10.1002/jmv.29751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29751</ArticleId><ArticleId IdType="pubmed">38884384</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicine Agency (EMA)  Replacement of Quadrivalent Seasonal Influenza Vaccines with Trivalent Vaccines in the EU. Removal of Antigens from B/Yamagata Lineage. EMA/123036/2024.  [(accessed on 13 September 2024)]; Available online:  https://www.ema.europa.eu/en/documents/other/replacement-quadrivalent-seasonal-influenza-vaccines-trivalent-vaccines-eu_en.pdf.</Citation></Reference><Reference><Citation>Li X., Gu M., Zheng Q., Gao R., Liu X. Packaging signal of influenza A virus. Virol. J. 2021;18:36. doi: 10.1186/s12985-021-01504-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01504-4</ArticleId><ArticleId IdType="pmc">PMC7890907</ArticleId><ArticleId IdType="pubmed">33596956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuentes-Muñoz N., Dutch R.E., Cattaneo R. Direct cell-to-cell transmission of respiratory viruses: The fast lanes. PLoS Pathog. 2018;14:e1007015. doi: 10.1371/journal.ppat.1007015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007015</ArticleId><ArticleId IdType="pmc">PMC6023113</ArticleId><ArticleId IdType="pubmed">29953542</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts K.L., Manicassamy B., Lamb R.A. Influenza A virus uses intercellular connections to spread to neighboring cells. J. Virol. 2015;89:1537–1549. doi: 10.1128/JVI.03306-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03306-14</ArticleId><ArticleId IdType="pmc">PMC4300760</ArticleId><ArticleId IdType="pubmed">25428869</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Zhu L., Liu F., Cheng L., Yao H., Wu N., Wu H., Li L. Generation and characterization of monoclonal antibodies against the hemagglutinin of H3N2 influenza A viruses. Virus Res. 2022;317:198815. doi: 10.1016/j.virusres.2022.198815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.198815</ArticleId><ArticleId IdType="pubmed">35595011</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki Y., Sugawara K., Nakauchi M., Takahashi Y., Onodera T., Tsunetsugu-Yokota Y., Matsumura T., Ato M., Kobayashi K., Shimotai Y., et al. Epitope mapping of the hemagglutinin molecule of A/(H1N1)pdm09 influenza virus by using monoclonal antibody escape mutants. J. Virol. 2014;88:12364–12373. doi: 10.1128/JVI.01381-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01381-14</ArticleId><ArticleId IdType="pmc">PMC4248900</ArticleId><ArticleId IdType="pubmed">25122788</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis W., Brown J.H., Cusack S., Paulson J.C., Skehel J.J., Wiley D.C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988;333:426–431. doi: 10.1038/333426a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/333426a0</ArticleId><ArticleId IdType="pubmed">3374584</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  Global Influenza Programme: Recommendations for Influenza Vaccine Composition.  [(accessed on 13 September 2024)]; Available online:  https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  US Will Transition to Trivalent Flu Vaccines for 2024–2025.  [(accessed on 13 September 2024)]; Available online:  https://www.cdc.gov/flu/spotlights/2023-2024/trivalent-vaccines-2024-2025.htm.</Citation></Reference><Reference><Citation>McLean H.Q., Belongia E.A. Influenza Vaccine Effectiveness: New Insights and Challenges. Cold Spring Harb. Perspect. Med. 2021;11:a038315. doi: 10.1101/cshperspect.a038315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a038315</ArticleId><ArticleId IdType="pmc">PMC8168527</ArticleId><ArticleId IdType="pubmed">31988202</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurel M., Pozo F., Pérez-Gimeno G., Buda S., Sève N., Oroszi B., Hooiveld M., Gomez V., Domegan L., Martínez-Baz I., et al. Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study. Influenza Other Respir. Viruses. 2024;18:e13243. doi: 10.1111/irv.13243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13243</ArticleId><ArticleId IdType="pmc">PMC10777262</ArticleId><ArticleId IdType="pubmed">38204584</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolarchuk C., Ickert C., Zelyas N., Kwong J.C., Buchan S.A. Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season. Euro Surveill. 2024;29:2300709. doi: 10.2807/1560-7917.ES.2024.29.2.2300709.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.2.2300709</ArticleId><ArticleId IdType="pmc">PMC10785209</ArticleId><ArticleId IdType="pubmed">38214082</ArticleId></ArticleIdList></Reference><Reference><Citation>Istituto Superiore di Sanità (ISS)   RespiVirNet: Sistema di Sorveglianza Integrata dei Virus Respiratori—Protocollo Operativo Stagione 2023–2024. ISS; Rome, Italy: 2024.  [(accessed on 13 September 2024)].  Available online:  https://respivirnet.iss.it/pagine/Documenti.aspx.</Citation></Reference><Reference><Citation>Costantino C., Mazzucco W., Graziano G., Maida C.M., Vitale F., Tramuto F. Mid-Term Estimates of Influenza Vaccine Effectiveness against the A(H1N1)pdm09 Prevalent Circulating Subtype in the 2023/2024 Season: Data from the Sicilian RespiVirNet Surveillance System. Vaccines. 2024;12:305. doi: 10.3390/vaccines12030305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030305</ArticleId><ArticleId IdType="pmc">PMC10976042</ArticleId><ArticleId IdType="pubmed">38543939</ArticleId></ArticleIdList></Reference><Reference><Citation>Frutos A.M., Price A.M., Harker E., Reeves E.L., Ahmad H.M., Murugan V., Martin E.T., House S., Saade E.A., Zimmerman R.K., et al. Interim Estimates of 2023–2024 Seasonal Influenza Vaccine Effectiveness—United States. MMWR Morb. Mortal. Wkly. Rep. 2024;73:168–174. doi: 10.15585/mmwr.mm7308a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7308a3</ArticleId><ArticleId IdType="pmc">PMC10907036</ArticleId><ArticleId IdType="pubmed">38421935</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker H., Findlay B., Zitha J., Goudie R., Hassell K., Evans J., Kalapotharakou P., Agrawal U., Kele B., Hamilton M., et al. Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom. Influenza Other Respir. Viruses. 2024;18:e13284. doi: 10.1111/irv.13284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13284</ArticleId><ArticleId IdType="pmc">PMC11109477</ArticleId><ArticleId IdType="pubmed">38773753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz de Lejarazu-Leonardo R., Montomoli E., Wojcik R., Christopher S., Mosnier A., Pariani E., Trilla Garcia A., Fickenscher H., Gärtner B.C., Jandhyala R., et al. Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes-Systematic Literature Review and Expert Consensus. Vaccines. 2021;9:1255. doi: 10.3390/vaccines9111255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111255</ArticleId><ArticleId IdType="pmc">PMC8621612</ArticleId><ArticleId IdType="pubmed">34835186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang M., Zanin M., Wong S.S. Subtype H3N2 Influenza A Viruses: An Unmet Challenge in the Western Pacific. Vaccines. 2022;10:112. doi: 10.3390/vaccines10010112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010112</ArticleId><ArticleId IdType="pmc">PMC8778411</ArticleId><ArticleId IdType="pubmed">35062773</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski D.M., Chuang E.S., Sabaiduc S., Kaweski S.E., Kim S., Dickinson J.A., Olsha R., Gubbay J.B., Zelyas N., Charest H., et al. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/2023. Euro Surveill. 2023;28:2300043. doi: 10.2807/1560-7917.ES.2023.28.5.2300043.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.5.2300043</ArticleId><ArticleId IdType="pmc">PMC9896608</ArticleId><ArticleId IdType="pubmed">36729117</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein E.J., Harvey W.T., Wilkie G.S., Shepherd S.J., MacLean A.R., Murcia P.R., Gunson R.N. Integrating patient and whole-genome sequencing data to provide insights into the epidemiology of seasonal influenza A(H3N2) viruses. Microb. Genom. 2018;4:e000137. doi: 10.1099/mgen.0.000137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000137</ArticleId><ArticleId IdType="pmc">PMC5857367</ArticleId><ArticleId IdType="pubmed">29310750</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis J., Laplante J., Shudt M., George K.S. Next generation sequencing for whole genome analysis and surveillance of influenza A viruses. J. Clin. Virol. 2016;79:44–50. doi: 10.1016/j.jcv.2016.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2016.03.005</ArticleId><ArticleId IdType="pubmed">27085509</ArticleId></ArticleIdList></Reference><Reference><Citation>European Union (EU)  Influenza-like Illness Definition. In Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the Communicable Diseases and Related Special Health Issues to Be Covered by Epidemiological Surveillance as well as Relevant Case Definitions.  [(accessed on 13 September 2024)].  Available online:  https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945.</Citation></Reference><Reference><Citation>Ministero della Salute  Direzione Generale della Prevenzione Sanitaria “Monitoraggio Dell’andamento Delle Forme Gravi e Complicate Di Malattia Da Virus Influenzali e/o da SARS-CoV-2 Confermate in Laboratorio, Stagione 2020–2021”—0042940-30/12/2020-DGPRE-DGPRE-P.  [(accessed on 13 September 2024)]; Available online:  https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=20 20&amp;codLeg=78081&amp;parte=1%20&amp;serie=null.</Citation></Reference><Reference><Citation>Zhou B., Donnelly M.E., Scholes D.T., St George K., Hatta M., Kawaoka Y., Wentworth D.E. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza A viruses. J. Virol. 2009;83:10309–10313. doi: 10.1128/JVI.01109-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01109-09</ArticleId><ArticleId IdType="pmc">PMC2748056</ArticleId><ArticleId IdType="pubmed">19605485</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura K., Stecher G., Kumar S. MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Mol. Biol. Evol. 2021;38:3022–3027. doi: 10.1093/molbev/msab120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msab120</ArticleId><ArticleId IdType="pmc">PMC8233496</ArticleId><ArticleId IdType="pubmed">33892491</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke D.F., Smith D.J. A recommended numbering scheme for influenza A HA subtypes. PLoS ONE. 2014;9:e112302. doi: 10.1371/journal.pone.0112302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0112302</ArticleId><ArticleId IdType="pmc">PMC4229193</ArticleId><ArticleId IdType="pubmed">25391151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R., Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Pac. Symp. Biocomput. 2002:310–322. doi: 10.1142/9789812799623_0029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1142/9789812799623_0029</ArticleId><ArticleId IdType="pubmed">11928486</ArticleId></ArticleIdList></Reference><Reference><Citation>Deem M.W., Pan K. The epitope regions of H1-subtype influenza A, with application to vaccine efficacy. Protein Eng. Des. Sel. 2009;22:543–546. doi: 10.1093/protein/gzp027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/gzp027</ArticleId><ArticleId IdType="pmc">PMC3307478</ArticleId><ArticleId IdType="pubmed">19578121</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez J.L., Lemus N., Lai T.Y., Mishra M., González-Domínguez I., Puente-Massaguer E., Loganathan M., Francis B., Samanovic M.I., Krammer F., et al. The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex. Vaccine. 2024;42:3365–3373. doi: 10.1016/j.vaccine.2024.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.04.037</ArticleId><ArticleId IdType="pmc">PMC11145762</ArticleId><ArticleId IdType="pubmed">38627145</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Riccio M., Caini S., Bonaccorsi G., Lorini C., Paget J., van der Velden K., Meijer A., Haag M., McGovern I., Zanobini P. Global analysis of respiratory viral circulation and timing of epidemics in the pre-COVID-19 and COVID-19 pandemic eras, based on data from the Global Influenza Surveillance and Response System (GISRS) Int. J. Infect. Dis. 2024;144:107052. doi: 10.1016/j.ijid.2024.107052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2024.107052</ArticleId><ArticleId IdType="pubmed">38636684</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control (CDC)  Influenza Virus Characterization: Summary Report, Europe, March 2024. WHO/EURO:2024-6189-45954-74223. Copenhagen: WHO Regional Office for Europe and Stockholm: European Centre for Disease Prevention and Control.  [(accessed on 13 September 2024)].  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/influenza-ECDC-WHO-Report-March-2024.pdf.</Citation></Reference><Reference><Citation>Costantino C., Restivo V., Amodio E., Colomba G.M.E., Vitale F., Tramuto F. A mid-term estimate of 2018/2019 vaccine effectiveness to prevent laboratory confirmed A(H1N1)pdm09 and A(H3N2) influenza cases in Sicily (Italy) Vaccine. 2019;37:5812–5816. doi: 10.1016/j.vaccine.2019.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.08.014</ArticleId><ArticleId IdType="pubmed">31427134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo C., Bella A., Alfonsi V., Puzelli S., Palmieri A.P., Chironna M., Pariani E., Piatti A., Tiberti D., Ghisetti V., et al. Influenza vaccine effectiveness in Italy: Age, subtype-specific and vaccine type estimates 2014/2015 season. Vaccine. 2016;34:3102–3108. doi: 10.1016/j.vaccine.2016.04.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.04.072</ArticleId><ArticleId IdType="pubmed">27154392</ArticleId></ArticleIdList></Reference><Reference><Citation>Okoli G.N., Racovitan F., Abdulwahid T., Righolt C.H., Mahmud S.M. Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studies after the 2009/2010 influenza pandemic. Vaccine. 2021;39:1225–1240. doi: 10.1016/j.vaccine.2021.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.01.032</ArticleId><ArticleId IdType="pubmed">33494964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissling E., Valenciano M., Pozo F., Vilcu A.M., Reuss A., Rizzo C., Larrauri A., Horváth J.K., Brytting M., Domegan L., et al. 2015/2016 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Influenza Other Respir. Viruses. 2018;12:423–437. doi: 10.1111/irv.12520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12520</ArticleId><ArticleId IdType="pmc">PMC6005601</ArticleId><ArticleId IdType="pubmed">29125681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissling E., Pozo F., Martínez-Baz I., Buda S., Vilcu A.M., Domegan L., Mazagatos C., Dijkstra F., Latorre-Margalef N., Kurečić Filipović S., et al. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I-MOVE primary care multicentre study. Influenza Other Respir. Viruses. 2023;17:e13069. doi: 10.1111/irv.13069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13069</ArticleId><ArticleId IdType="pmc">PMC9835407</ArticleId><ArticleId IdType="pubmed">36702797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissling E., Maurel M., Emborg H.D., Whitaker H., McMenamin J., Howard J., Trebbien R., Watson C., Findlay B., Pozo F., et al. Interim 2022/2023 influenza vaccine effectiveness: Six European studies, October 2022 to January 2023. Euro Surveill. 2023;28:2300116. doi: 10.2807/1560-7917.ES.2023.28.21.2300116.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.21.2300116</ArticleId><ArticleId IdType="pmc">PMC10283457</ArticleId><ArticleId IdType="pubmed">37227299</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenciano M., Kissling E., Reuss A., Jiménez-Jorge S., Horváth J.K., Donnell J.M., Pitigoi D., Machado A., Pozo F., I-MOVE Multicentre Case Control Study Team The European I-MOVE Multicentre 2013–2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2) Vaccine. 2015;33:2813–2822. doi: 10.1016/j.vaccine.2015.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.04.012</ArticleId><ArticleId IdType="pubmed">25936723</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurel M., Howard J., Kissling E., Pozo F., Pérez-Gimeno G., Buda S., Sève N., McKenna A., Meijer A., Rodrigues A.P., et al. Interim 2023/2024 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024;29:2400089. doi: 10.2807/1560-7917.ES.2024.29.8.2400089.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.8.2400089</ArticleId><ArticleId IdType="pmc">PMC10899813</ArticleId><ArticleId IdType="pubmed">38390651</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasugi M., Nakamura S., Daidoji T., Kawashita N., Ramadhany R., Yang C.S., Yasunaga T., Iida T., Horii T., Ikuta K., et al. Frequency of D222G and Q223R hemagglutinin mutants of pandemic (H1N1) 2009 influenza virus in Japan between 2009 and 2010. PLoS ONE. 2012;7:e30946. doi: 10.1371/journal.pone.0030946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030946</ArticleId><ArticleId IdType="pmc">PMC3281909</ArticleId><ArticleId IdType="pubmed">22363521</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Wang W., Zhou H., Suguitan A.L., Jr., Shambaugh C., Kim L., Zhao J., Kemble G., Jin H. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J. Virol. 2010;84:44–51. doi: 10.1128/JVI.02106-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02106-09</ArticleId><ArticleId IdType="pmc">PMC2798434</ArticleId><ArticleId IdType="pubmed">19864389</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Tzeng W.P., Horner L., Kamal R.P., Tatum H.R., Blanchard E.G., Xu X., York I., Tumpey T.M., Katz J.M., et al. Influence of Immune Priming and Egg Adaptation in the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses After Influenza Vaccination in Adults. J. Infect. Dis. 2018;218:1571–1581. doi: 10.1093/infdis/jiy376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy376</ArticleId><ArticleId IdType="pmc">PMC8974399</ArticleId><ArticleId IdType="pubmed">29931203</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Reiser W.K., Tan T.J.C., Lv H., Rivera-Cardona J., Heimburger K., Wu N.C., Brooke C.B. Natural variation in neuraminidase activity influences the evolutionary potential of the seasonal H1N1 lineage hemagglutinin. Virus Evol. 2024;10:veae046. doi: 10.1093/ve/veae046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veae046</ArticleId><ArticleId IdType="pmc">PMC11196192</ArticleId><ArticleId IdType="pubmed">38915760</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuley J.L., Gilbertson B.P., Trifkovic S., Brown L.E., McKimm-Breschkin J.L. Influenza Virus Neuraminidase Structure and Functions. Front. Microbiol. 2019;10:39. doi: 10.3389/fmicb.2019.00039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.00039</ArticleId><ArticleId IdType="pmc">PMC6362415</ArticleId><ArticleId IdType="pubmed">30761095</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 2006;5:1015–1025. doi: 10.1038/nrd2175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2175</ArticleId><ArticleId IdType="pmc">PMC7097821</ArticleId><ArticleId IdType="pubmed">17139286</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrukee R., Gunalan V., Maurer-Stroh S., Reading P.C., Hurt A.C. Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution. J. Virol. 2022;96:e0091822. doi: 10.1128/jvi.00918-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00918-22</ArticleId><ArticleId IdType="pmc">PMC9364793</ArticleId><ArticleId IdType="pubmed">35867563</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Vries E., Stelma F.F., Boucher C.A. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 2010;363:1381–1382. doi: 10.1056/NEJMc1003749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1003749</ArticleId><ArticleId IdType="pubmed">20879894</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunker M., Villafuerte D.A., Fall A., Norton J.M., Abdullah O., Rothman R.E., Fenstermacher K.Z.J., Morris C.P., Pekosz A., Klein E., et al. Genomic evolution of influenza during the 2023–2024 season, the johns hopkins health system. J. Clin. Virol. 2024;174:105718. doi: 10.1016/j.jcv.2024.105718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2024.105718</ArticleId><ArticleId IdType="pmc">PMC11384212</ArticleId><ArticleId IdType="pubmed">39079210</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC)   Expert Opinion on Neuraminidase Inhibitors for the Prevention and Treatment of Influenza—Review of Recent Systematic Reviews and Meta-Analyses. ECDC; Stockholm, Sweden: 2017.  [(accessed on 13 September 2024)].  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/Scientific-advice-neuraminidase-inhibitors-2017.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>